Lineage Cell Therapeutics

Lineage Cell Therapeutics R&D per Employee

The R&D Spending per Employee of Lineage Cell Therapeutics (LCTX) as of Oct 31, 2026 is 230,246.75 USD. In the previous year, R&D Spending per Employee was 161,974.03 USD — a change of 42.15% (higher).

R&D per Employee

230,246.75USD

YoY

42.15%

Last updated:

R&D Spending per Employee of Lineage Cell Therapeutics is 2025 230,246.75 USD. R&D Spending per Employee of Lineage Cell Therapeutics was 2024 161,974.03 USD. It decreases by 42.15% higher compared to the previous year.

The Lineage Cell Therapeutics R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
272,142.86 USD
Jan 1, 2019
233,090.91 USD
Jan 1, 2020
159,961.04 USD
Jan 1, 2021
440,441.56 USD
Jan 1, 2022
181,649.35 USD
Jan 1, 2023
203,961.04 USD
Jan 1, 2024
161,974.03 USD
Jan 1, 2025
230,246.75 USD
The Lineage Cell Therapeutics R&D per Employee history
YEARR&D per EmployeeYoY
230,246.75USD+42.15%
161,974.03USD-20.59%
203,961.04USD+12.28%
181,649.35USD-58.76%
440,441.56USD+175.34%
159,961.04USD-31.37%
233,090.91USD-14.35%
272,142.86USD-12.77%
312,000.00USD-33.46%
468,909.09USD-15.25%
553,298.70USD+13.51%
487,436.66USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lineage Cell Therapeutics Stock analysis

What does Lineage Cell Therapeutics do? Lineage Cell Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of cell therapies for various diseases. Originally established in 1990 as VisiGenics Inc., specializing in proteomic and genetic analysis, the company later changed its name to Lineage Cell Therapeutics Inc. to reflect its focus on the research and development of stem cell therapies. Lineage Cell Therapeutics develops and markets cell therapy products based on its own patents and discoveries, including therapies for eye, neurodegenerative, and cancer diseases. The company's proprietary technology platform gives it a crucial position in the field of cell therapy. Additionally, Lineage Cell Therapeutics collaborates with academic institutions and other biopharmaceutical companies to expedite the process of commercializing cell therapies. The company offers a wide range of cell therapies for various injuries and diseases, with key applications including: - OPC1: A cell-based therapy for spinal cord injuries caused by damage to the spinal cord. This therapy is being developed on the astrocyte differentiation treatment platform derived from embryonic stem cells (ES cells). - OpRegen: A cell-based regenerative product for dry age-related macular degeneration (tAMD). This therapy is based on the retinal pigment epithelium cell differentiation treatment platform derived from human embryonic stem cells. - VAC: An immunotherapy for cancer treatment. This treatment involves dendritic cells isolated from the patient's blood and genetically modified to present cancer-specific antigens. The goal is to stimulate the patient's immune system to trigger a specific immune response against cancer. Lineage Cell Therapeutics also pursues a strong expansion strategy. In 2020, it acquired a majority stake in AgeX Therapeutics, a biotechnology company focused on developing innovations in the field of stem cells. This acquisition strengthened the company's capacity for innovation and increased its ability to capitalize on future growth opportunities through partnerships, licensing, and product launches. Overall, Lineage Cell Therapeutics has become a significant player in the field of cell therapy, thanks to the use of cutting-edge technology and years of experience in the life science industry. One of the company's main goals is to develop and manufacture groundbreaking cell therapies to ultimately improve the lives of patients worldwide. Lineage Cell Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lineage Cell Therapeutics stock

R&D Spending per Employee of Lineage Cell Therapeutics is 230,246.75 USD in 2025.

R&D Spending per Employee of Lineage Cell Therapeutics changed from 161,974.03 USD to 230,246.75 USD, representing a 42.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Lineage Cell Therapeutics since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Lineage Cell Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Lineage Cell Therapeutics

All Key Metrics — Lineage Cell Therapeutics